WallStSmart

Cyclerion Therapeutics Inc (CYCN)vsModerna Inc (MRNA)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Moderna Inc generates 117163% more annual revenue ($2.23B vs $1.90M). CYCN leads profitability with a 0.0% profit margin vs -141.4%. MRNA earns a higher WallStSmart Score of 21/100 (F).

CYCN

Avoid

21

out of 100

Grade: F

Growth: 5.3Profit: 2.5Value: 6.7Quality: 3.5
Piotroski: 1/9

MRNA

Avoid

21

out of 100

Grade: F

Growth: 2.7Profit: 2.0Value: 6.7Quality: 7.5
Piotroski: 3/9Altman Z: 2.09
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

CYCNUndervalued (+65.9%)

Margin of Safety

+65.9%

Fair Value

$3.58

Current Price

$3.36

$0.22 discount

UndervaluedFair: $3.58Overvalued
MRNAUndervalued (+70.0%)

Margin of Safety

+70.0%

Fair Value

$134.97

Current Price

$143.97

$9.00 discount

UndervaluedFair: $134.97Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CYCN1 strengths · Avg: 8.0/10
Price/BookValuation
2.8x8/10

Reasonable price relative to book value

MRNA2 strengths · Avg: 9.0/10
Market CapQuality
$56.02B9/10

Large-cap with strong market position

Debt/EquityHealth
0.199/10

Conservative balance sheet, low leverage

Areas to Watch

CYCN4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$17.23M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Piotroski F-ScoreQuality
1/93/10

Weak financial health signals

MRNA4 concerns · Avg: 3.3/10
Price/BookValuation
8.5x4/10

Trading at 8.5x book value

Revenue GrowthGrowth
2.1%4/10

2.1% revenue growth

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Return on EquityProfitability
-46.6%2/10

ROE of -46.6% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : CYCN

The strongest argument for CYCN centers on Price/Book.

Bull Case : MRNA

The strongest argument for MRNA centers on Market Cap, Debt/Equity.

Bear Case : CYCN

The primary concerns for CYCN are EPS Growth, Market Cap, Profit Margin.

Bear Case : MRNA

The primary concerns for MRNA are Price/Book, Revenue Growth, Piotroski F-Score.

Key Dynamics to Monitor

CYCN profiles as a value stock while MRNA is a turnaround play — different risk/reward profiles.

CYCN carries more volatility with a beta of 1.75 — expect wider price swings.

MRNA is growing revenue faster at 2.1% — sustainability is the question.

CYCN generates stronger free cash flow (-1M), providing more financial flexibility.

Bottom Line

CYCN scores higher overall (21/100 vs 21/100). MRNA offers better value entry with a 70.0% margin of safety. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Cyclerion Therapeutics Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, is dedicated to the discovery, development, and commercialization of drugs for serious diseases of the central nervous system (CNS). The company is headquartered in Cambridge, Massachusetts.

Moderna Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.

Want to dig deeper into these stocks?